caa a22 4500 475805992 CHVBK 20180406123747.0 cr unu---uuuuu 170329e20000601xx s 000 0 eng 10.1023/A:1026588028780 doi (NATIONALLICENCE)springer-10.1023/A:1026588028780 Nesbit Mark Department of Antiangiogenesis, Aventis-Gencell, Hayward, California, USA aut Abrogation Of Tumor Vasculature Using Gene Therapy [Elektronische Daten] [Mark Nesbit] Anti-angiogenic gene therapy may be rational approach in the treatment of solid tumors. The current state of gene therapy with regard to the abrogation of tumor vasculature is reviewed in this article and the different administration vehicles are noted. Furthermore, this article discusses the influence of vascular support cells in the tumor vasculature and choice of pre-clinical model for anti-angiogenic cancer gene therapy. Kluwer Academic Publishers, 2000 angiogenesis nationallicence gene therapy nationallicence tumor nationallicence adenovirus nationallicence Cancer and Metastasis Reviews Kluwer Academic Publishers 19/1-2(2000-06-01), 45-49 0167-7659 19:1-2<45 2000 19 10555 https://doi.org/10.1023/A:1026588028780 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1026588028780 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Nesbit Mark Department of Antiangiogenesis, Aventis-Gencell, Hayward, California, USA aut NATIONALLICENCE 773 0- Cancer and Metastasis Reviews Kluwer Academic Publishers 19/1-2(2000-06-01), 45-49 0167-7659 19:1-2<45 2000 19 10555 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer